Maia Biotechnology Inc (MAIA) Stock Price, Quote & News

Company Profile

MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Industry: Biotechnology

Sector: Healthcare

Phone: 312 416 8592

Website: maiabiotech.com

Address:

444 West Lake Street, Suite 1700, Chicago, United States

lookingaroundhere Mar. 14 at 4:27 PM

$MAIA re-opening a position here and adding sub $1.50 next week.

0 · Reply

Chemaster Mar. 13 at 4:36 AM

$MAIA Just created an unofficial Reddit community for $MAIA to archive and preserve my more detailed posts. Couldn't find any official or active MAIA subreddit. https://www.reddit.com/r/MAIABiotech/

1 · Reply

Chemaster Mar. 13 at 4:01 AM

$MAIA The 2028 patent cliff poses a $170-350B revenue risk for Big Pharma through 2032, with oncology heavyweights like Merck's Keytruda ($30B annual sales) losing U.S. exclusivity, enabling biosimilars and generics to erode markets—driving urgent M&A (e.g., $173B in at-risk sales by 2032) for innovative assets like MAIA Biotechnology ($MAIA) THIO to fill gaps in immuno-oncology pipelines. THIO's differentiated mechanism, high Phase 3 success probability (96-99% Bayesian), and pan-cancer appeal make it a prime partnership/acquisition target for firms like Merck ($MRK), Bristol Myers Squibb ($BMY), or Pfizer ($PFE) seeking post-cliff growth in a $668B oncology market by 2034. More Information at MAIA Unofficial Reddit Community https://www.reddit.com/r/MAIABiotech/comments/1rscru9/2028_patent_cliff_for_big_pharma/

0 · Reply

DiamondDog33 Mar. 12 at 7:16 PM

$MAIA THE NEWBIES DONT UNDERSTAND WHAT LARGE SCALE MEANS ......maybe fully completed by ..oh 2029/2030 LOL ....300

0 · Reply

Zenlama Mar. 12 at 6:02 PM

$MAIA

0 · Reply

tradeordie24 Mar. 12 at 12:36 PM

$MAIA $3+ soon??

1 · Reply

Chemaster Mar. 12 at 1:37 AM

$MAIA Direct quote, "the views in the report reflect that of Diamond Equity Research"

0 · Reply

ReturnOfEsquire Mar. 12 at 1:17 AM

$MAIA Diamond Equity is not independent...need to read the whole thing, folks.

1 · Reply

DiamondDog33 Mar. 11 at 9:33 PM

$MAIA CLASSIC ....Sucker born every minute

0 · Reply

tradeordie24 Mar. 11 at 7:52 PM

$MAIA when $4-5?

0 · Reply

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

Mar 4, 2026, 4:00 PM EST - 11 days ago

MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock

Mar 2, 2026, 5:00 PM EST - 13 days ago

MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Feb 24, 2026, 8:45 AM EST - 19 days ago

MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market

Jan 20, 2026, 10:15 AM EST - 7 weeks ago

MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum

Dec 24, 2025, 8:01 AM EST - 2 months ago

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Dec 16, 2025, 4:15 PM EST - 3 months ago

MAIA Biotechnology Announces $1.51 Million Private Placement

Dec 11, 2025, 1:00 PM EST - 3 months ago

MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates

Dec 10, 2025, 2:00 PM EST - 3 months ago

MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach

Dec 1, 2025, 9:17 AM EST - 3 months ago

MAIA Biotechnology Announces Open Market Purchases by CEO and Directors

Nov 21, 2025, 9:01 AM EST - 4 months ago

MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025

Oct 27, 2025, 10:45 AM EDT - 4 months ago

MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 23, 2025, 8:36 AM EDT - 5 months ago

MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

Oct 13, 2025, 4:20 PM EDT - 5 months ago

MAIA Biotechnology Announces $736,600 Private Placement

Oct 7, 2025, 8:47 AM EDT - 5 months ago

MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets

Sep 29, 2025, 4:30 PM EDT - 5 months ago

MAIA Biotechnology Announces $2.25 Million Private Placement

Sep 24, 2025, 8:01 AM EDT - 6 months ago

MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent

Sep 5, 2025, 9:03 AM EDT - 6 months ago

MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer

Aug 27, 2025, 9:01 AM EDT - 7 months ago

MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells

Jul 28, 2025, 8:01 AM EDT - 8 months ago

MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer

Jul 17, 2025, 9:17 AM EDT - 8 months ago

MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy

Jul 9, 2025, 9:15 AM EDT - 8 months ago

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

Jul 1, 2025, 9:00 AM EDT - 9 months ago

MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

Jun 24, 2025, 8:15 AM EDT - 9 months ago

MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

Jun 18, 2025, 9:15 AM EDT - 9 months ago

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

Jun 10, 2025, 8:46 AM EDT - 9 months ago

MAIA Biotechnology to Present at BIO International Convention 2025

Jun 5, 2025, 2:28 PM EDT - 10 months ago

MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients

Jun 5, 2025, 11:10 AM EDT - 10 months ago

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial

Jun 5, 2025, 8:04 AM EDT - 10 months ago

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer

May 27, 2025, 5:35 PM EDT - 10 months ago

CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000

May 27, 2025, 4:30 PM EDT - 10 months ago

MAIA Biotechnology Announces Private Placement of Approximately $669,500

May 15, 2025, 11:05 AM EDT - 10 months ago

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 14, 2025, 10:15 AM EDT - 10 months ago

MAIA Biotechnology Announces Director Participation in Recent Private Placement

May 5, 2025, 11:45 PM EDT - 11 months ago

CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement

May 5, 2025, 4:05 PM EDT - 11 months ago

MAIA Biotechnology Announces $1.08 Million Private Placement

Apr 1, 2025, 8:30 AM EDT - 1 year ago

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

Mar 25, 2025, 8:46 AM EDT - 1 year ago

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

Mar 20, 2025, 9:20 AM EDT - 1 year ago

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

Mar 19, 2025, 11:00 AM EDT - 1 year ago

MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO

Feb 27, 2025, 8:51 AM EST - 1 year ago

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

Feb 26, 2025, 8:47 AM EST - 1 year ago

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

Feb 24, 2025, 4:30 PM EST - 1 year ago

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

Feb 18, 2025, 3:44 PM EST - 1 year ago

MAIA Biotechnology Announces Private Placement of $2,715,000

Feb 4, 2025, 8:51 AM EST - 1 year ago

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

Jan 10, 2025, 9:45 AM EST - 1 year ago

MAIA Biotechnology to Present at Biotech Showcase 2025

Dec 19, 2024, 8:47 AM EST - 1 year ago

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

Dec 16, 2024, 8:37 AM EST - 1 year ago

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

Dec 9, 2024, 6:00 PM EST - 1 year ago

MAIA Biotechnology Announces Private Placement of Approximately $950,000

Dec 3, 2024, 8:17 AM EST - 1 year ago

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

Nov 7, 2024, 8:47 AM EST - 1 year ago

MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement

lookingaroundhere Mar. 14 at 4:27 PM

$MAIA re-opening a position here and adding sub $1.50 next week.

0 · Reply

Chemaster Mar. 13 at 4:36 AM

$MAIA Just created an unofficial Reddit community for $MAIA to archive and preserve my more detailed posts. Couldn't find any official or active MAIA subreddit. https://www.reddit.com/r/MAIABiotech/

1 · Reply

Chemaster Mar. 13 at 4:01 AM

0 · Reply

DiamondDog33 Mar. 12 at 7:16 PM

$MAIA THE NEWBIES DONT UNDERSTAND WHAT LARGE SCALE MEANS ......maybe fully completed by ..oh 2029/2030 LOL ....300

0 · Reply

Zenlama Mar. 12 at 6:02 PM

$MAIA

0 · Reply

tradeordie24 Mar. 12 at 12:36 PM

$MAIA $3+ soon??

1 · Reply

Chemaster Mar. 12 at 1:37 AM

$MAIA Direct quote, "the views in the report reflect that of Diamond Equity Research"

0 · Reply

ReturnOfEsquire Mar. 12 at 1:17 AM

$MAIA Diamond Equity is not independent...need to read the whole thing, folks.

1 · Reply

DiamondDog33 Mar. 11 at 9:33 PM

$MAIA CLASSIC ....Sucker born every minute

0 · Reply

tradeordie24 Mar. 11 at 7:52 PM

$MAIA when $4-5?

0 · Reply

lookingaroundhere Mar. 10 at 9:46 PM

$MAIA it's almost lift off here.

1 · Reply

Mindscan Mar. 9 at 7:44 PM

$MAIA 1.50 is the median because of that offer. Sucks short term but could have been a lower offer price as well. We will go up from here on interim results and other news 💪💪💪

0 · Reply

Chemaster Mar. 9 at 7:00 PM

$MAIA Agree, especially since In June 2025, MAIA entered into a master clinical supply agreement with Roche to support future studies combining THIO with Roche's anti-PD-L1 checkpoint inhibitor Tecentriq (atezolizumab) for hard-to-treat cancers. Preclinical data showed strong synergy between THIO and atezolizumab, and this partnership enables potential combination trials (e.g., in NSCLC or other indications).

1 · Reply

Cashflow62 Mar. 9 at 6:59 PM

$MAIA Back in......

0 · Reply

MoneyHelix Mar. 9 at 6:38 PM

$MAIA Roche's drug giredestrant just failed to meet it's clinical objectives in a Phase 3 study. Roche could be looking for new assets to add to their portfolio to fill that gap 🥂 MAIA's Phase 3 and Phase 2D clinical data is becoming increasingly valuable 🥂

0 · Reply

Chemaster Mar. 9 at 5:10 PM

$MAIA Only three things are need for success. Cash, data and patience 1. MAIA currently has 30M which is plenty for interim results 2. Diamond Equity Research, an independent equity research firm analysts view MAIA as "well-positioned" scientifically, with a 96-99% Bayesian probability of Phase 3 success based on prior data. 3. Patience – The stock market is the method of transferring money from the impatient to the patient. Once, the interim data revealed, Big Pharms will be throwing money and deals MAIA’s way considering the 2028 Patent Cliff. NFA DYOR

1 · Reply

Find_the_Cure Mar. 9 at 4:34 PM

$MAIA dead cat bounce?

0 · Reply

Mindscan Mar. 9 at 4:15 PM

$MAIA False start of the week. I decided to sell them all at open around 1.49 and went in on EONR, I don't always have luck with these pump stocks but now I did, sold for an almost 20% profits and went back in on Maia with more shares, bought at Market price to help us up again. Maia remains a long term investment to me. Close to 12K shares now, might go to 15K, stay strong in these rough times 💪💪💪

0 · Reply

selftaught Mar. 9 at 2:31 PM

$MAIA was originally wanting in at 1.72. glad I moved on to different plays. Yikes. Watching here again though

1 · Reply

CARTE_BLANCHE_DEVEREAUX Mar. 9 at 2:05 AM

$GLSI $MAIA $IBRX Is bio a safer segment in this market? Is IBRX gonna bleed til Q1? Are P2 companies worth investing in? We will be talking about this and more...

1 · Reply

vividC Mar. 8 at 2:30 PM

$MAIA If MAIA has ~15–25 evaluable patients in the 180 mg expansion cohort, they could report preliminary confirmed responses (ORR) in an abstract in ASCO end of May. I am sort of thinking that they wheeled in the investment because they are on track for that.

2 · Reply

lookingaroundhere Mar. 6 at 5:10 PM

$MAIA Is the warrant price post offering $1.50? I might have to get back in here.

2 · Reply

Market Cap	59.15M
Revenue (ttm)	0.00
Net Income (ttm)	-23.25M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	662,100
Avg Vol	1,148,196
Day's Range	N/A - N/A
Shares Out	38.66M
Stochastic %K	69%
Beta	-0.04
Analysts	Sell
Price Target	$14.00